Phase 2 (~50% of patients evaluated to date at 12 months) shows 46% lesion growth reduction vs. controlThere are no OCU410-related serious ...
Developer Embark Studios releases a new ARC Raiders update for January 2026, as patch 1.11.0 brings some big balance ...
Maze Therapeutics uses its Compass genetics platform to advance kidney and obesity drugs, with MZE829 Phase 2 data due in ...
Now firmly in the back half of the 2020s, one megatrend that we’re all aware of is how the experience economy has caused a ...
Study supports favorable safety and tolerability profile and clinically meaningful functional and structural benefits in ...
Morning Overview on MSN
These 'blindness' genes were once a 100% curse, and scientists were wrong
For decades, a genetic test that turned up a mutation linked to inherited blindness was treated as a verdict, not a risk ...
Dungeons & Dragons' bloody handed new subclass is part Bhaalspawn, part Dark Urge, all teleporting terror - here's how to ...
Ocugen has announced the publication of positive results from its phase 1 GARDian1 trial of OCU410ST, a gene therapy for ...
Indeed, this question was posed directly to Rebel Wolves creative director Mateusz Tomaskiewicz this week. In an interview ...
The Torchlight Infinite Vorax season adds new grafting mechanics, high-risk hero Vendetta Erika, and a UI overhaul to make it ...
As medical device manufacturers face mounting pressures to reduce environmental risk, improve traceability, and accelerate ...
According to MarketsandMarkets™, the Synthetic Feed Additives Market is projected to grow from USD 33.88 billion in 2025 and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback